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IL-38 has an anti-inﬂammatory action in
psoriasis and its expression correlates with
disease severity and therapeutic response
to anti-IL-17A treatment
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Emanuela Gubinelli6, Cinzia Mazzanti5, Andrea Cavani7, Menotti Ruvo 4, Charles A. Dinarello8,9,
Cristina Albanesi 1 and Stefania Madonna1
Abstract
IL-36 cytokines, a subgroup of IL-1 family, comprise IL-36α, IL-36β, and IL-36γ agonists, abundantly expressed in
psoriatic skin, and IL-36RA and IL-38 antagonists. In psoriatic skin, IL-36 cytokines interfere with keratinocyte
corniﬁcation programs and induce the release of antimicrobial peptides and chemokines active on neutrophils and
Th17 lymphocytes. To date, the role of IL-38 antagonist in psoriasis remains to be deﬁned. Here, we demonstrate that
skin and circulating IL-38 levels are reduced in psoriatic patients and in other skin diseases characterized by
neutrophilic inﬁltrate. In psoriasis, the balance of IL-36γ agonist/IL-38 antagonist serum levels is in favor of agonists and
is closely associated with disease severity. Interestingly, IL-38 is upregulated by anti-IL-17A biological treatment and
positively correlates with the therapeutic efﬁcacy of secukinumab in psoriatic patients. The downregulation of IL-38
expression is strictly related to keratinocyte de-differentiation triggered by the inﬂammatory cytokines IL-36γ, IL-17,
and IL-22. Finally, we demonstrate that administration of recombinant full-length IL-38 counteracts in vitro the
biological processes induced by IL-36γ in human keratinocytes and endothelial cells and attenuates in vivo the severity
of the psoriasiform phenotype induced by IMQ in mice. Such effects are achieved by restoring the physiological
programs of keratinocyte proliferation and differentiation, and reducing the immune cell inﬁltrates.
Introduction
Psoriasis is an immune-mediated skin disease in which
interferon (IFN)-γ, tumor necrosis factor (TNF)-α, inter-
leukin (IL)-17, and IL-22 cytokines, released by Th1 and
Th17 lymphocytes1,2, have a pathogenic action by pro-
moting hyperproliferation, interfering with the terminal
differentiation and inducing the secretion of pro-
inﬂammation molecules by keratinocytes3,4. A growing
number of studies demonstrated that also IL-36 cytokines
are pathogenic drivers of psoriasis5,6. IL-36s belong to IL-
1 family and comprise three agonists, IL-36α, IL-36β, and
IL-36γ, and two receptor antagonists IL-36RA and IL-387.
IL-36 agonists are strongly expressed in psoriatic skin of
individuals affected by plaque psoriasis and generalized
pustular psoriasis. Here, these cytokines have inﬂamma-
tory effects on many cell targets, mainly keratinocytes, by
interfering with their corniﬁcation programs and inducing
the release of antimicrobial peptides and chemokines
active on neutrophils and Th17 lymphocytes8. IL-36s also
promote proliferation and migration of human dermal
microvascular endothelial cell (HDMEC), thus
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contributing to the dermal capillary dilatation typical of
psoriatic lesions9. Although human T lymphocytes do not
express the IL-36R receptor (IL-36R), IL-36 cytokines
indirectly promote Th17 lymphocyte polarization by
activating the maturation of dendritic cells10–12. IL-17,
together with TNF-α and IL-22, upregulates IL-36
themselves leading to a local auto-ampliﬁcation loop13.
The role of IL-36 agonists in the pathogenesis of psoriasis
has been widely demonstrated. Capon et al. recently
showed that IL-36R blockade by IL-36Ra or a neutralizing
IL-36R antibody decreases the inﬂammation in ex vivo
and in vivo experimental models of psoriasis14. However,
the role of IL-36 antagonists, in particular of IL-38,
remains yet undeﬁned. Mutations in IL-36Ra have been
described as a cause of pustular psoriasis, owing to an
impaired inhibitory activity of IL-36Ra on Th17 respon-
ses15–17. In parallel, IL-38 allelic variants have been cor-
related to rheumatic diseases, including psoriatic
arthritis18. IL-38 is a 17–18 kDa protein sharing 40%
sequence similarity with IL-1RA and IL-36Ra antagonists
and elicits its antagonistic effects through binding to IL-
36 receptor, as IL-36Ra7,17. IL-38 is dramatically reduced
in the epidermis of psoriatic lesions as compared with
uninvolved or healthy skin, in line with its reduced
expression observed in de-differentiated keratinocytes
compared with differentiated cells19,20. IL-38 reduction is
peculiar of chronic psoriatic skin, as its expression is
contrarily induced in synovial tissues of patients with
rheumatoid arthritis and in colonic inﬂamed biopsies of
patients with Chron’s disease19. Interestingly, IL-38 has
anti-inﬂammatory effects on mouse models of arthritis
and on a model of retinopathy, where it suppresses the
secretion of chemokines involved in Th17 pathway and
inhibits the pathological processes of vascularization,
respectively21,22.
In this study, we analyzed the potential involvement of IL-
38 in psoriasis by evaluating its circulating and skin levels in
affected patients before and after the biological inhibition of
IL-17A with secukinumab. Furthermore, we investigated
the effects of IL-38 administration in both in vitro and
in vivo experimental models of psoriasis, such as in human
keratinocyte and endothelial cell cultures activated by pro-
inﬂammatory cytokines related to psoriasis, as well as in the
IMQ-induced murine model of skin inﬂammation.
Results
Skin levels of IL-38 are reduced in psoriatic patients and in
other skin diseases characterized by neutrophilic inﬁltrate
Aimed at clarifying the controversial IL-38 expression in
psoriatic and healthy skin19,23, levels of IL-38, together with
IL-36Ra and IL-36γ, were analyzed in psoriatic specimens,
including non-lesional (NLS) skin, and skin overlapping
pre-lesional (Pre-LS) and lesional (LS T0) zones of target
plaques by immunohistochemistry. As shown in Fig. 1a, a
strong cytoplasmic expression of IL-38 was observed
throughout the epidermis of NLS areas (panel i), as well as
of healthy skin (Fig. S1, panel i), whereas a lower immu-
noreactivity was detected in dermal endothelial cells and
ﬁbroblasts. During the transition from Pre-LS to LS T0 area
of the same skin biopsy, IL-38 staining progressively
decreased in the epidermis (Fig. 1a, panel ii). This reduction
was more evident in LS areas, where IL-38 expression was
moderately detected in the proliferative layer of epidermis,
but it was absent in suprabasal layers (Fig. 1a, panel iii). IL-
36Ra and IL-36γ were minimally expressed in NLS (Fig. 1a,
panels i) and healthy specimens (Fig. S1, panel i), whereas
their levels were enhanced in the upper layers of pre-LS and
LS T0 epidermis (Fig. 1a, panels ii and iii). Inﬁltrating
immune cells were also positive for IL-36γ and IL-38 in pre-
LS and LS T0 skin, in accordance with IL-36γ staining
previously detected in macrophages, dendritic cells, and
Langerhans cells24 (mean percentage of IL-36γ+ cells: 10 ±
1.2% and 38 ± 1.4% in pre-LS and LS T0 skin, respectively;
IL-38+ cells: 15 ± 1.1% and 35 ± 1.9% in pre-LS and LS
T0 skin, respectively, Fig. 1a, panels ii and iii). Contrarily,
immune cells inﬁltrating psoriatic dermis were quite
negative for IL-36Ra (Fig. 1a, panels ii and iii). IL-38 epi-
dermal downregulation was observed in other inﬂammatory
skin diseases, characterized by a diffuse neutrophilic inﬁl-
trate, where modest levels of IL-38 were observed only in
the upper layers of the epidermis (Fig. S1, panels ii, iii, iv).
Vice versa, a higher, but variable, immunoreactivity for IL-
38 was detected throughout the epidermis of lesional AD
(Fig. S1, panel v). Differently from IL-38, IL-36Ra, and IL-
36γ were upregulated in the epidermis of Hidradenitis
suppurativa (HS), Sweet Syndrome (SS), Pyoderma Gang-
renosum (PG), and Atopic Dermatitis (AD), as compared
with healthy skin, with different localization among dis-
orders. In particular, IL-36Ra and IL-36γ expression was
diffuse throughout the epidermis of PG and AD (Fig. S1,
panels iv and v), whereas it was localized in the upper and
lower layers of HS and SS epidermis, respectively (panels ii
and iii). In all diseased skin biopsies, a modest IL-38
expression was observed in immune cells inﬁltrating the
dermis (Fig. S1, panels i–v). Here, with the exception of AD,
a relevant percentage of IL-36Ra+ and IL-36γ+ cells with a
neutrophil-like morphology was observed in immune cells.
IL-38 is upregulated by anti-IL-17A treatment and
correlates to the therapeutic efﬁcacy to secukinumab
To evaluate the effects of anti-IL-17A treatment on IL-
38, its expression was analyzed in vivo in skin biopsies
taken 8 weeks after therapy with secukinumab from the
same target plaques analyzed at baseline. As shown in
Fig. 1a (panel iv), IL-38 positivity increased in skin of
secukinumab-treated patients (mean of LS T8: 2.8 ± 0.3)
as compared with levels before treatment (mean of LS T0:
1.0 ± 0.2, p ≤ 0.05), becoming similar to those observed in
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NLS or healthy skin (mean of NLS: 3.0 ± 0.3) Fig. 1a and
Fig. S1, respectively, panels i). Contrarily, IL-36Ra and IL-
36γ staining was strongly downregulated (IL-36Ra: 0.9 ±
0.3 in LS T8 vs 2.9 ± 0.1 in LS, p ≤ 0.05; IL-36γ: 1.0 ± 0.2 in
LS T8 vs 3.0 ± 0.1 in LS, p ≤ 0.05), according to previous
observations (Fig. 1a, panels iv)24,25. IL-38 mRNA levels
also increased in skin after 8-week therapy, compared
with those detected before treatment (means: 215.0 in LS
T8 vs 82.5 in LS T0, p ≤ 0.05), whereas IL-36Ra and IL-
36γ mRNA was reduced (IL-36Ra: 295.0 in LS T8 vs 52.5
in LS T0, p ≤ 0.05; IL-36γ: 215.0 in LS T8 vs 15.5 in LS T0,
p ≤ 0.05) (Fig. 1b). Next, we investigated the potential
systemic relevance of IL-38 by measuring its levels in
serum of psoriatic patients before and after secukinumab.
At baseline, IL-38 levels were signiﬁcantly lower in
psoriatic patients than in healthy donors, and were
upregulated following secukinumab (155.0 in Pso T8 vs
95.0 in Pso T0, p ≤ 0.05) (Fig. 1c). IL-36Ra and IL-36γ
serum release was instead increased at baseline of the
same psoriatic patients, compared with healthy group
(means of IL-36Ra: 490.0 in Pso T0 vs 355.0 in healthy,
p ≤ 0.05; IL-36γ: 255.0 in Pso T0 vs 115.0 in healthy, p ≤
0.05), and reduced by anti-IL-17A therapy (means of IL-
36Ra: 490.0 in Pso T0 vs 150.0 in Pso T8, p ≤ 0.05; IL-36γ:
255.0 in Pso T0 vs 135.0 in Pso T8, p ≤ 0.05) (Fig. 1c). As
shown in Fig. 1d, the ratio of serum IL-36γ/IL-38 levels in
psoriatic patients strongly correlated to the disease
activity as determined by psoriasis area and severity index
(PASI) scores (r= 0.51, p < 0.01). The ratio of serum levels
of IL-38, but not of IL-36Ra, after and before secukinu-
mab resulted to be closely associated with the resolution
of the clinical psoriatic manifestations (r= 0.51, p < 0.01,
and i= 0.094, p= 0.65, respectively), evaluated as per-
centage of PASI reduction determined after and before
treatment (Fig. 1e, f).
IL-38 and IL-36Ra expression is differently regulated in
human keratinocytes
As IL-36 cytokines inhibit keratinocyte terminal differ-
entiation during psoriasis development26, we investigated
IL-38 expression in post-conﬂuent keratinocyte cultures,
resembling differentiated cells of the epidermal suprabasal
layer11,27. Keratinocytes, but not HDMEC, constitutively
expressed and released IL-38 and, at lower extent, IL-
36Ra (Fig. 2a, b). IL-38 and IL-36Ra were also expressed
in sub-conﬂuent (proliferating) keratinocyte cultures in
basal condition, even though at reduced levels as com-
pared with differentiated cultures (approximately ﬁvefolds
lower, data not shown). mRNA expression and release of
IL-38 were signiﬁcantly downregulated by IL-17A in post-
conﬂuent keratinocyte cultures, whereas they were not
inﬂuenced by TNF-α (Fig. 2a, b). In parallel, IL-17A and
TNF-α, alone and, at higher extent in combination, sig-
niﬁcantly induced IL-36γ and IL-36Ra (Fig. 2a, b). mRNA
and protein levels of IL-36γ were also signiﬁcantly
induced in HDMECs, but at a lower extent compared with
keratinocytes (Fig. 2a, b). Interestingly, IL-38 levels were
also strongly downregulated by IL-22 and, at a lower
extent, by IFN-γ and IL-36γ in keratinocytes (Fig. 2c, d).
Vice versa, in line with literature data28, we found that IL-
36γ was induced by IL-36γ itself, whereas it was not
inﬂuenced by IFN-γ and IL-22 (Fig. 2c, d). IL-36Ra was
also upregulated in keratinocytes by IL-36γ, but not
inﬂuenced by IFN-γ and IL-22 (Fig. 2c, d). As a whole,
these data demonstrate that keratinocytes are the main
producers of IL-38 in resident skin cells, and its expres-
sion is downregulated by inﬂammatory cytokines.
IL-38 counteracts the biological processes induced by IL-
36γ in human keratinocytes and dermal vascular
endothelial cells
As shown in Fig. 3a, similarly to IL-36Ra7,29, IL-38
inhibited the phosphorylation of P38 MAPK and the
subunit P65 of NFκB induced by IL-36γ (Fig. 3a). Other
than inducing the expression of chemokines attracting
neutrophils and T cells, IL-36 cytokines interfere with
keratinocyte differentiation in organotypic models by
downregulating ﬁlaggrin8,13. We thus analyzed the effects
of IL-38 on differentiation and inﬂammatory responses
induced by IL-36γ in keratinocytes. As shown in Fig. 3b,
(see ﬁgure on previous page)
Fig. 1 IL-38 levels are reduced in skin and serum of psoriatic patients and upregulated by secukinumab treatment. a IHC for IL-38, IL-36Ra,
and IL-36γ (all stained in red-brown) was performed on parafﬁn-embedded sections of biopsies obtained from psoriatic skin (n= 8) including not
lesional (NLS) (i), proximal-to-lesion (Pre-LS) (ii), lesional zones of evolving plaques, before (LS T0) (iii) and after 8 weeks (LS T8) (iv) of secukinumab
treatment. Sections were counterstained with Mayer’s H&E. One out of eight representative stainings of psoriatic skin biopsies are shown. Bars,
100 μm. Graphs show the mean of four-stage score values for IL-38, IL-36Ra, and IL-36γ ± SD epidermal expression per three different ﬁelds of all six
sections. *p ≤ 0.05, as assessed by Mann–Whitney U test. bmRNA expression of IL-38, IL-36Ra, and IL-36γ were analyzed by RT-PCR on healthy, NLS, LS
T0, and LS T8 biopsies (n= 10) and normalized to HPRT-1 levels. c Cytokine levels were analyzed by ELISA in serum obtained by venous blood of
healthy (n= 25) and psoriatic individuals (n= 25) before (Pso T0) and after (Pso T8) secukinumab treatment. b, c The results are shown as individual
values and mean. *p ≤ 0.05; p** ≤ 0.01, as assessed by Mann–Whitney U test. d Correlation between the ratio of IL-36γ and IL-38 serum levels and PASI
(psoriasis area and severity index) at baseline. e, f Correlations between the ratio of IL-38 or IL-36Ra between T8 and T0 and Δ PASI (Δ PASI, calculated
as percentage of PASI reduction) score in psoriatic individuals after secukinumab treatment. Spearman’s test was used for correlation analysis. r
indicates the strength of the linear relationship, n indicates the number of values in each plot, and p value shows the probability that the slope of the
true relationship is zero. p ≤ 0.05 was considered signiﬁcant
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post-conﬂuent keratinocyte cultures expressed higher
levels of differentiation markers, such as KRT1 and
KRT10 and loricrin, compared with proliferating cells
(T0), and their expression was abrogated by IL-36γ.
Interestingly, IL-38 dose-responsively upregulated and
normalized the levels of KRT1, KRT10, and loricrin, but
not those of ΔNp63, a typical marker of proliferating
keratinocytes. Similarly, IL-36Ra increased KRT1, KRT10,
and loricrin levels in IL-36γ-treated keratinocytes,
although these effects were more evident at lower doses,
compared with IL-38 (Fig. 3b). IL-38 also reduced the IL-
36γ-induced expression of CXCL8, CXCL20, IL-6, and
vascular endothelial growth factor A (VEGF-A), as well as
of antimicrobial peptides HBD-2 and LL-37, although a
dose–response was not observed (Fig. 3c). At high doses,
IL-36Ra counteracted the expression of most inﬂamma-
tory mediators more efﬁciently than IL-38 (Fig. 3c). IL-38
also downregulated the IL-36γ-induced expression of
intercellular adhesion molecule 1 (ICAM-1), with a sig-
niﬁcant reduction at higher dose (Fig. 3d). HDMEC also
express IL-36 receptor and, upon IL-36γ, they express
pro-inﬂammatory chemokines and adhesion molecules,
whose levels are reduced by IL-36Ra30. IL-36γ not only
synergizes with TNF-α in the release of these inﬂamma-
tory mediators, but it induces proliferation of cultured
HDMEC. As shown in Fig. S2, IL-38 inhibited the phos-
phorylation of ERK1/2 strongly induced by IL-36γ in
HDMEC, as well as that of P65 (panel a). Interestingly,
HDMEC proliferation induced by IL-36γ was signiﬁcantly
attenuated by IL-38 (Fig. S2b). IL-38, similarly to IL-36Ra,
also reverted the IL-36γ- and TNF-α-induced expression
of inﬂammatory molecules in HDMEC cultures
(Fig. S2b–d).
IL-38 ameliorates the psoriasiform phenotype of IMQ-
treated mice
We further investigated IL-38 potential in IMQ-induced
psoriasiform dermatitis, an IL-17/IL-22-mediated mouse
model of the disease31. Subcutaneous injection of IL-38
for 5 days, concomitantly to topical IMQ application,
ameliorated the psoriasiform manifestations, with a ~ 40%
reduction of acanthosis and consequent scale thickness, as
Fig. 2 Regulation of the expression and release of IL-38, IL-36Ra, and IL-36γ cytokines by psoriasis-related cytokines in human
keratinocytes and endothelial cells. a, c IL-38, IL-36Ra, and IL-36γ mRNA expression was detected by real-time PCR in keratinocyte cultures
undergoing terminal differentiation (4 days post conﬂuency) and HDMEC cultures stimulated with IL-17A (50 ng/ml) and TNF-α (50 ng/ml for
keratinocytes and 10 ng/ml for HDMEC), alone or in combination a or in keratinocytes stimulated with IL-22 (50 ng/ml), IFN-γ (200 U/ml, or IL-36γ
(50 ng/ml) c, for 6 h. GAPDH mRNA levels were detected for normalization. b, d IL-36 cytokine levels were analyzed by ELISA in supernatants obtained
by cell cultures after 24 h cytokine stimulation. All data shown are the mean of three different experiments. *p ≤ 0.01 and **p ≤ 0.001 compared with
untreated cultures, as assessed by Mann–Whitney U test
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well as of the dermal inﬂammatory inﬁltrate (~ 50%
decrease) (Fig. 4a–e). As shown in Fig. 5, epidermal dif-
ferentiation markers, such as KRT10, which are normally
expressed in the suprabasal layers of epidermis, displayed
a broad staining throughout keratinocyte layers of IMQ-
induced skin lesions (Fig. 5a, b). Interestingly, adminis-
tration of IL-38 normalized the expression of KRT10,
which compartmentalized to the upper granular layers, as
typically observed in normal epidermis (Fig. 5a). A
reduced number of proliferating Ki67+ keratinocytes was
also observed in IL-38-treated inﬂamed skin (Fig. 5a, b).
In addition, the epidermis of IL-38-treated mice showed a
reduced expression of the pro-angiogenic VEGF-A cyto-
kine, compared with controls (Fig. 5a, b). IL-38 treatment
also decreased the number of inﬁltrating CD3+ T lym-
phocytes and Ly6G+ neutrophils (panels iii), compared
with IMQ-treated mice group (panels ii), whereas it did
not inﬂuence the number of CD11c+ cells (panels ii and
iii). Both IL-36Ra and IL-38 administration determined a
signiﬁcant reduction of the endogenous levels of IL-36Ra
Fig. 3 IL-38 inhibits IL-36γ-induced P38 and NF-κB signalings, as well as regulates the expression of differentiation markers and
inﬂammatory molecules in human keratinocytes. All experiments were performed on keratinocyte cultures (n= 3 strains) undergoing terminal
differentiation and stimulated or not with IL-36γ in presence or absence of the indicated doses of IL-38 or IL-36Ra. a Protein extracts were obtained
from keratinocyte cultures stimulated for 24 h and subjected to WB analysis to detect P38 and P65 phosphorylation. Filters were probed with anti-P38
and -P65 Abs. b Keratinocyte cultures were analyzed for KRT1, KRT10, Loricrin and ΔNp63 expression by WB. a, b β-actin was used as loading control
and DI ratio indicates the densitometric intensity of the indicated phosphorylated/unphosphorylated proteins shown in one representative of three
different WB. c mRNA levels of CXCL8, CCL20, VEGF-A, IL-6, HBD-2, and LL-37 were detected by real-time PCR analysis in keratinocytes stimulated for
6 h and normalized for GAPDH mRNA levels. TNF-α treatment was used as positive control. d ICAM-1 expression was evaluated by ﬂow cytometry
analysis on keratinocytes stimulated for 24 h with IL-36γ (50 ng/ml) and shown as mean ﬂuorescence intensity. All data shown are the mean of three
different experiments. c *p ≤ 0.05 and p** ≤ 0.01 compared with untreated or IL-36γ-treated cultures, as assessed by Mann–Whitney U test
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(~ 30% decrease of relative mRNA expression) and IL-36γ
(~ 35% decrease), whereas they did not inﬂuence endo-
genous IL-38 expression (data not shown). In parallel, also
CCL20, CXCL8, and IL-6 mRNA expression was down-
regulated in the skin of IL-38-treated mice group (data
not shown). Finally, similarly to IL-38, IL-36Ra amelio-
rated the psoriasiform phenotype, with positive effects on
all pathological markers analyzed (Fig. 5, panels iv).
Discussion
In this study, we identify IL-38 as a new responsive
biomarker for psoriasis, and demonstrate its anti-
inﬂammatory properties in in vitro and in vivo experi-
mental models of psoriasis. The interest toward IL-38 in
psoriatic context arises from our and earlier observations
that its expression is reduced in the epidermis of skin
lesions and in the serum of psoriatic patients, as com-
pared with uninvolved or healthy skin, and is inverse to
those of IL-36Ra, a well-characterized antagonist of IL-36
cytokines strongly induced in psoriatic lesions32. We
found that the balance of IL-36γ agonist/IL-38 antagonist
levels, but not of IL-36γ/IL-36Ra, in serum of psoriatic
patients is closely associated with disease severity. Inter-
estingly, IL-38 expression is responsive to IL-17A inhibi-
tion, as its levels signiﬁcantly increase in skin and in
serum of affected patients after treatment with secuki-
numab, a selective anti-IL-17A antibody used in clinical
practise33, whereas IL-36γ and IL-36Ra levels decrease in
line with previous studies24,25. We show that the ratio of
IL-38 serum levels after and before secukinumab corre-
lates to the therapeutic efﬁcacy in psoriatic patients, thus
identifying IL-38 as a potential responsive biomarker for
psoriasis. However, these ﬁndings need to be further
conﬁrmed on a larger cohort of psoriatic patients treated
by secukinumab and other biologicals, such as antibodies
blocking TNF-α, a strong inducer of IL-36 agonists.
Fig. 4 Ameliorative effects of IL-38 administration on pathological changes of IMQ-induced psoriasiform murine skin lesions. a
Macroscopic views of back skin from mice left untreated (IMQ-) (i), IMQ-treated (IMQ+ ) (ii) or co-treated with IMQ and IL-38 (IMQ+ /IL-38) (iii) or IMQ
and IL-36Ra (IMQ+ /IL-36Ra) (iv), both subcutaneously injected, after 5 days. b Representative H&E staining of untreated (i), treated with IMQ cream
(ii), in presence of IL-38 (iii) or IL-36Ra (iv). Bars, 500 μm. Subcutaneous injection of IL-38 or IL-36Ra reverted the phenotypic skin changes determined
by IMQ. The quantiﬁcations of epidermal c, scale thickness d, and immune cell inﬂux e were analyzed as parameters of skin acanthosis and
inﬂammation. Graphs show means of microns of epidermis and stratum corneum thickness, and mean of number of inﬁltrating immune cells
per section (n= 3 sections) ± S.D. per group (n= 8 mice). p* ≤ 0.01 and **p ≤ 0.001 compared with untreated or IMQ-treated groups, as assessed by
unpaired Student‘s t test
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Fig. 5 IL-38 reverts the pathological markers in IMQ-induced murine model of psoriasis. a (i), IMQ-treated (n= 8) (ii) and co-treated with IMQ
and IL-38 (IMQ+ /IL-38) (n= 8) (iii) or IL-36Ra (IMQ+ /IL-36Ra) (n= 8) (iv) shows an upregulated and normalized expression of KRT10 in the
epidermis after IL-38 and IL-36Ra treatment, as well as a reduction of VEGF-A expression, and of positive Ki67, Ly6G, CD3, and CD11c cells. Sections
were counterstained with Mayer’s H&E and were visually evaluated by a pathologist experienced in dermatology. One out of eight representative
stainings is shown. Bars, 500 μm. b Graphs show the mean of number of positive cells or of four-stage score values for KRT10 ± SD per three sections
per experimental group (six of eight mice were analyzed). *p ≤ 0.01, **p ≤ 0.001 compared with untreated or IMQ-treated groups, as assessed by
unpaired Student‘s t test
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Taken together, our ﬁndings unveil a relevant role of IL-
38 in psoriasis, supporting the hypothesis that the dysre-
gulation of its expression could be pathogenic in psoriasis.
IL-38 and IL-36Ra antagonists have anti-inﬂammatory
properties by antagonizing the IL-36 pathways through a
direct binding to IL-36 receptor with similar afﬁnities5,7.
However, the upregulation of IL-36Ra alone might be not
sufﬁcient to unleash IL-36-dependent inﬂammatory
responses in psoriatic lesions, where several cytokines
inducing IL-36 are active on resident skin and immune
cells. Owing to the different in vitro and in vivo expres-
sion of IL-38 and IL-36Ra, IL-38, and IL-36Ra can be
considered as not redundant cytokines, having IL-38
additional functions closely related to the keratinocyte
differentiation. In fact, the loss of IL-38 in the suprabasal
layers of psoriatic epidermis is associated with the
impaired differentiation processes occurring in the affec-
ted skin, to which IL-17 and IL-22 cytokines markedly
contribute1,34. In support of this hypothesis, our results
show that keratinocytes undergoing terminal differentia-
tion release higher levels of IL-38 compared with IL-36Ra.
However, IL-17, IL-22, and IL-36γ, known to inhibit the
terminal keratinocyte differentiation8,20, have inhibitory
effects on IL-38 expression, although they induce IL-36Ra
antagonist. A predictive analysis of potential transcrip-
tional factor-binding sites on IL-38 and IL-36Ra promoter
sequences revealed the presence in the promoter of IL-38,
but not of IL-36Ra, of elements likely binding to cAMP-
responsive repressors, such as E4BP4 and ICER, and
Kruppel-like factors, known to be induced by inﬂamma-
tory cytokines and related to keratinocyte differentia-
tion35–37. These factors could be responsible for IL-38
downregulation in keratinocytes subjected to de-
differentiative processes triggered by IL-36γ, IL-17A,
and IL-22. IL-38 expression varies in different disease
settings, especially in disorders with dysregulated IL-1-
dependent responses, such as spondylitis ankylopoetica,
rheumatoid arthritis, and HS. In our study, we found that
the local decline of IL-38, and the concomitant induction
of IL-36γ and IL-36Ra in psoriatic epidermis, are common
to other inﬂammatory skin diseases characterized by a
prominent neutrophilic inﬁltrate, including not only HS,
but also Sweet’s syndrome and PG, where an altered
epidermal architecture has been reported38,39. Contrarily,
a modest IL-38 expression has been found in skin affected
by AD, an immune-mediated skin disease characterized
by a prominent Th2 lymphocyte inﬁltrate and lacking of
neutrophil circuits40, thus, supporting the involvement of
the IL-36 cytokine axis in cutaneous skin disorders
determined by neutrophil presence. Furthermore, we
investigated the effects of IL-38 reinforcement in in vitro
and in vivo models of psoriasis. In line with data reported
by Boutet et al., we found that the endogenous expression
of IL-38 is signiﬁcantly reduced in the skin of IMQ-
induced mice, whereas that of IL-36Ra is induced and
correlates with IL-36γ upregulation, thus reﬂecting the
expression pattern of these cytokines in psoriatic skin
lesions. Interestingly, we demonstrate that the adminis-
tration of IL-38 signiﬁcantly attenuates the severity of
psoriasiform phenotype induced by IMQ, by restoring the
physiological proliferation and differentiation programs in
keratinocytes, and decreasing the expression of VEGF-A,
a cytokine involved in the altered angiogenic processes
occurring in psoriasis41. IL-38 reduces inﬁltration of
T cells and neutrophils in IMQ model, accordingly with a
signiﬁcant reduction of psoriasis-related chemokines
involved in T-cell and neutrophil recruitment and acti-
vation. The ameliorative impact of IL-38 on the psoriatic
clinical phenotype is also associated with the decrease of
IL-36 local expression, and was comparable to that
observed with IL-36Ra, whose anti-inﬂammatory prop-
erties have been recently demonstrated also in an ex vivo
model of human psoriasis16. Recently, Palomo et al.42
demonstrated that the depletion of IL-38, differently from
IL-36Ra, does not affect the severity of the psoriasiform
reactions in IMQ-treated mice. These results are not
surprising if we consider that endogenous IL-38 is per se
absent in skin of this mouse model, whereas IL-36Ra is
upregulated. In our opinion, IL-38 reinforcement could be
the better experimental approach to evaluate its function
in inﬂammatory skin conditions, and the ameliorative
effects of the IL-38 administration in IMQ model conﬁrm
our thesis.
In our study, contrarily to what observed in vivo in
IMQ-induced model, the anti-inﬂammatory effects of IL-
38 and IL-36Ra are not entirely comparable in vitro, being
IL-36Ra able to inhibit, at the same doses, the inﬂam-
matory responses more efﬁciently than IL-38. This dis-
crepancy can be explained considering that we use a full-
length IL-38, whereas IL-36Ra was employed in a more
active, N-terminally cleaved, form7,43. As two N-
terminally cleaved forms of IL-38 with an increased
inhibitory activity have been identiﬁed in tumor cells44,
we hypothesize that IL-38 is processed in our in vivo
experimental system, likely owing to extracellular neu-
trophil proteases abundantly released in the IMQ-treated
skin31,45,46. Finally, the absence of a dose–response effect
of IL-38 (as well as of IL-36Ra) on in vitro expression of
inﬂammatory mediators support the hypothesis of
Dinarello et al. that IL-38 and IL-36Ra do not behave as
classic receptor antagonists5. Upon binding to IL-36R, IL-
38, and IL-36Ra might recruit an inhibitory co-receptor at
low concentrations, but a signaling co-receptor at higher
concentrations, similarly to what observed for IL-375. In
summary, IL-38 has strong anti-inﬂammatory effects on
IL-36-induced responses in the psoriatic skin context,
making it an attractive cytokine to explore also in other
Th17-related diseases characterized by dysregulated IL-1-
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driven responses. Clinical trials with an IL-36R blocking
antibody (ANB019) are ongoing in generalized pustular
psoriasis and palmoplantar pustular psoriasis. These stu-
dies represent the ﬁrst attempt to block inﬂammatory
responses executed by epidermal keratinocytes, the pri-
mary source of IL-36 cytokines. However, the reinforce-
ment of IL-38 could represent an alternative therapeutic
strategy for inhibiting IL-36-induced responses in psor-
iasis, although understanding the functional biology of IL-
38 in skin context will be needed to reveal its role in new
mechanisms of disease and to evaluate the potential
impact of its manipulation in psoriasis treatment.
Materials and methods
Human subjects
Twenty-ﬁve patients with mild-to-severe chronic plaque
psoriasis (4 ≤ PASI ≥ 45), and 25 healthy subjects under-
going plastic surgery were enrolled in this study (age
range 18–70 years). Psoriatic patients had similar char-
acteristics, including age of onset and disease duration
and, after an induction phase, they received subcutaneous
injections of 300mg Secukinumab once a week (Cosentyx,
Novartis).
Biopsies were taken from skin plaques at sites over-
lapping LS before treatment (T= 0) and the adjacent Pre-
LS. Biopsies at LS sites after 8-week treatment (T= 8) and
at NLS, 3 cm distant from the evolving plaques, were also
taken from the same psoriatic patients. In parallel, skin
biopsies were also taken by healthy volunteers undergoing
plastic surgery, and from lesional skin areas of patients
with HS, SS, PG, and AD. Among individuals, 8 were
selected for immunohistochemical and 10 for RT-PCR
studies, whereas all 25 were analyzed for IL-36 serum
quantiﬁcation. This study was approved by the Ethical
Committee of the IDI-IRCCS Hospital, Rome (registra-
tion no.: IDI-IMM-IL36pso) and performed accordingly
to the Declaration of Helsinki. Informed consent was
signed by all study subjects.
Cell cultures and treatments
Normal human keratinocytes were established from
sun-protected skin of healthy individuals (n= 4) and
cultured as previously reported47. Cells were plated at
5000/cm2 and maintained to 4-d post conﬂuency. High-
conﬂuence cultures were stimulated with recombinant
human IL-22 (50 ng/ml), IFN-γ (200 U/ml), IL-17A
(50 ng/ml), TNF-α (50 ng/ml), or IL-36γ (Ser18-Asp169;
50 ng/ml) (R&D Systems, Minneapolis, MN, USA) in
keratinocyte basal medium (Clonetics).
HDMEC previously isolated from foreskin of three dif-
ferent donors48 were retrieved from the Cell Bank of the
Laboratory of Experimental Immunology of IDI-IRCCS
and stimulated with TNF-α (10 ng/ml), IL-17A (50 ng/
ml), IFN-γ (200 U/ml), or IL-36γ (50 ng/ml) in endothelial
basal medium (EBM, Lonza) containing 2% fetal bovine
serum (starvation medium). When necessary, both cell
types were treated with recombinant human IL-38 or IL-
36Ra (mature form Val2-Asp155; R&D Systems) con-
comitantly to cytokine stimulation.
Recombinant expression and puriﬁcation of IL-38
A single Gibson block (gblock, IDT technologies) was
produced encoding for an N-terminal 6xHis tag, a
thrombin cleavage site, and full-length IL-38 (152 resi-
dues). This gblock was PCR ampliﬁed for insertion into
pET21 using a single NdeI site and subsequently expres-
sed in BL21/DE3 cells in loria broth supplemented with
100mg/ml ampicillin. Cells were grown until an optical
density (600 nm) of ~ 0.6 and induced for 3–4 h prior to
harvesting. The full-length protein was also frown in
M9 minimal media to obtain 15N-labeled protein in order
to conﬁrm that IL-38 was well-folded (data not shown).
For IL-38 puriﬁcation, cell pellets were sonicated on ice
in lysis buffer (50 mM Na2HPO4, pH 7.5, 500 mM NaCl,
10 mM imidazole), centrifuged to remove cellular debris,
and applied to a Ni-afﬁnity column (GE Healthcare Life
Sciences. IL-38 was eluted using lysis buffer supplemented
with 400 mM imidazole. Fractions comprising IL-38 were
dialyzed against “Q buffer” (50 mM tris, pH 8.0, 50 mM
NaCl, 10 mM imidazole, 1 mM dithiothreitol), applied to
a Q-sepharose fast ﬂow column (GE Healthcare Life
Sciences). Finally, fractions comprising IL-38 were con-
centrated, cleaved with thrombin at room temperature
overnight to remove the 6xHis tag, and applied to a
Superdex-75 (GE Healthcare Life Sciences) in “ﬁnal buf-
fer” (10 mM HEPES, pH 70, 150mM NaCl). IL-38 was
concentrated and stored at − 80 °C until further use.
IMQ-induced psoriasiform model
Eight-week-old female BALB/cJ mice (Harlan Labora-
tories, San Pietro al Natisone, Italy) treated for 5 con-
secutive days with 5% (62.5 mg) IMQ (ALDARA cream,
Meda AB, Solna, Sweden)49 received daily subcutaneous
injections (1 μg/mouse) of human recombinant full-
length IL-38 (n= 8), Val2-Asp155 IL-36Ra (n= 8), or
control vehicle (PBS) (n= 8), starting on day 0 of IMQ
administration. A mice group (n= 3), not receiving IMQ,
was used as negative control. On day 5, full thickness skin
biopsies of the treated area were collected with an eight-
mm biopsy puncher. Skin was either snap frozen in liquid
N2 for total RNA preparation, or ﬁxed in neutral buffered
formalin (Sigma-Aldrich, St. Louis, MO, USA) for histo-
pathological analysis. The whole experiment was repeated
twice with similar results. All mouse procedures were
carried out in accordance with institutional standard
guidelines. The experimental design has been authorized
by the Italian Health Minister (protocol No. SA-IDI-13-
CA-1).
Mercurio et al. Cell Death and Disease          (2018) 9:1104 Page 10 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
Immunohistochemistry
Parafﬁn-embedded sections were obtained from biop-
sies of psoriatic skin including LS at baseline (T= 0) and
after 8-week Cosentyx treatment, Pre-LS and NLS zones
of evolving plaques, as well as of healthy skin. Parafﬁn-
embedded sections obtained from patients affected by HS,
AD, SS, or PG syndromes were retrieved by Histo-
pathology Unit at IDI-IRCCS hospital.
Immunohistochemistry analyses were performed with
primary antibodies against IL-38 (InVitrogen, Carlsbad,
CA, USA), IL-36Ra (AbCam, Cambridge, UK) and IL-36γ
(AbCam). Secondary biotinylated mAbs and staining kits
(Vector Laboratories, Burlinagame, CA, USA) were used
to develop IL-38 and IL-36Ra immunoreactivities,
whereas biotinylated secondary Ab and staining kit from
Scytek (Logan, Utah, USA) was used for IL-36γ detection.
Parafﬁn-embedded sections were obtained from murine
skin tissues and analyzed for epidermal and scale thick-
ness, as well as cell inﬁltrate number. Average epidermal
and scale thickness was quantiﬁed by a researcher blind to
the experimental groups who took ﬁve measurements per
three sections for each mouse. Cells inﬁltrating dermis
were also counted in three skin sections for each mouse.
Immunohistochemistry analyses were performed with
primary Abs against CD3 (Dako, Glostruk, Denmark),
CD11c (Dako, Glostruk, Denmark), Ly6G (BD Bios-
ciences, Franklin Lakes, NJ USA), Ki67 (Novocastra,
Newcastle upon Tyne, UK), KRT10 (Covance, Princeton,
NJ, USA), VEGF-A (Santa Cruz Biotechnology) and
immunoreactivities developed with secondary biotiny-
lated mAbs and staining kits (Vector Laboratories, Bur-
lingame, CA, USA). All sections were counterstained with
Mayer’s Hematoxylin and eosin and positivity was eval-
uated in ﬁve adjacent ﬁelds at a magniﬁcation × 200.
A semiquantitative, four-stage scoring system was
applied, ranging from negative immunoreactivity (0) to
strong immunoreactivity (4+) for IL-36 cytokines in
human skin, as well as for KRT10 and VEGF-A in murine
skin. IL-36 cytokine-positive cells were counted blindly by
two observers with an eyepiece graticule at a magniﬁca-
tion of × 200. For each skin specimen, two sections were
analyzed for each staining and positive cells were eval-
uated in ﬁve adjacent ﬁelds.
RNA isolation and real-time RT-PCR
Total RNA from keratinocytes and endothelial cells was
extracted using the TRIzol reagent (InVitrogen), whereas
total RNA from human and mouse skin biopsies by RNeasy
Lipid Tissue Kit (Qiagen, Chatsworth, CA, USA). mRNA
was reverse-transcribed into complementary DNA and
analyzed by real-time PCR. GAPDH or β-2 microglobulin
were used as housekeeping genes for human and murine
mRNA, respectively. Primer pairs used in PCR reactions are
listed in the table reported in Supplementary Table S1.
Fluorescence intensity was analyzed by the ABI PRISM SDS
7000 PCR Instrument (Applied Biosystems, Branchburg, NJ,
USA), using SYBR Green PCR reagents or Taqman PCR
Master Mix. The values obtained from triplicate experi-
ments were averaged, and data are presented as means ± SD.
Cytokine quantiﬁcation by ELISA
Concentrations of IL-38, IL-36Ra, and IL-36γ were
measured in serum obtained by venous blood of patients
enrolled in this study, as well as in cell-free supernatants
from untreated or cytokine-treated keratinocyte and
endothelial cell cultures, using speciﬁc ELISA kits (BD
Pharmingen). The plates were analyzed in an ELISA
reader mod.3550 UV (Bio-Rad Hercules, CA, USA).
Western blotting analysis
Total protein extracts by cell cultures and immunoblot-
ting were performed as previously reported36. The Abs
employed for the study were as follows: anti-phospho-Erk1/
2 (E-4), anti-Erk1/2 (C16), anti-β-actin (C-11), all provided
by Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
phospho-P65, anti-P65, anti-phospho-P38, and ant-P38
were from Cell Signaling Technology (Denvers, MA,
USA), whereas anti-KRT1, anti-KRT10, and anti-loricrin
were from Covance (Emeryville, CA, USA). Anti-ΔNp63 Ab
was provided by Santa Cruz Biotechnology. Filters were
properly developed with anti-mouse, anti-goat, or anti-
rabbit Ig Abs conjugated to horseradish peroxidase using
the ECL-plus detection system (Amersham, Dubendorf,
Switzerland), or, otherwise, the SuperSignal West Femto kit
(Pierce, Rockford, IL, USA). Immunoblots were subjected to
densitometry using an Imaging Densitometer model GS-
670 (Bio-Rad) supported by the Molecular Analyst software,
and band intensities were evaluated in three independent
experiments. Data are expressed as densitometric intensity
(DI) ± SD.
HDMEC proliferation
In total, 6 × 104 HDMEC were seeded in 12-well plates
in endothelial growth medium in triplicate for each con-
dition. 1 day after, the cells were starved in EBM and
treated with IL-36γ alone or in presence of recombinant
IL-38 or IL-36Ra and cultured for 24 and 48 h. The
number of viable cells was determined by a trypan blue
exclusion test.
Flow cytometry analysis
Keratinocyte and HDMEC membrane expression of
ICAM-1 was evaluated using allophycocyanin (APC)-
conjugated anti-CD54 monoclonal Ab (clone 84H10;
Immunotech, Marseille, France), whereas VCAM
expression on HDMEC membrane was detected by using
APC-conjugated anti-human VCAM-1 (clone 51-10C9,
BD Pharmingen). Cells were analyzed by a FACScan
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equipped with Cell Quest software (Becton Dickinson,
Mountain View, CA, USA).
Statistical analysis
Differences between groups were evaluated by the
Mann–Whitney U or unpaired Student‘s t test as speciﬁed
in the ﬁgure legends using GraphPad prism Software (La
Jolla, CA, USA). Spearman’s test was used to correlation
analysis.
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